Market Overview

Edison Investment Research Comments on Halozyme Therapeutics on Multiple Value Drivers

Related HALO
Halozyme Announces Resumption of Patient Enrollment, Dosing in PEGPH20 Clinical Trial
Benzinga's Top Initiations
Halozyme Shares Plummet as Concerns Halt Trial (Fox Business)

In a report published Friday, Edison Investment Research analyst Jason Zhang commented on recent developments related to Halozyme Therapeutics (NASDAQ: HALO).

In the report, Edison Investment Research noted, “With a positive CHMP opinion received for Herceptin SC, Halozyme is moved a step closer to being able to reap the full commercial potential of its rHuPH20 platform, which is being used to develop subcutaneous (sc) formulations of leading IV drugs for Roche and other partners. This opportunity currently drives Halozyme's valuation, but we contend that the market is ignoring certain key pipeline assets, notably PEGPH20, which is in a Phase II study in pancreatic cancer.”

Halozyme Therapeutics closed on Wednesday at $7.69.

Posted-In: Edison Investment Research Jason ZhangAnalyst Color Analyst Ratings

 

Most Popular

Related Articles (HALO)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters